SCHEMBL24214171

SCHEMBL24214171

CC(O)c1cc(C(=O)O)ccc1C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 3/20 0.43
AKR1C2 P52895 3/20 0.43
SRD5A2 P31213 2/20 0.41
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40
KIF11 P52732 1/20 0.40
ACE2 Q9BYF1 1/20 0.40
NOTUM Q6P988 1/20 0.40
PDE2A O00408 1/20 0.39
TTR P02766 2/20 0.39
HPGD P15428 1/20 0.39
F11 P03951 2/20 0.38
GRM1 Q13255 2/20 0.38
MEN1 O00255 1/20 0.38
CYP1A2 P05177 1/20 0.38
KMT2A Q03164 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MRGPRX4 Q96LA9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24214167 0.83 NOTUM (0.61) NOTUMHPGDMEN1KMT2ATDP1
SCHEMBL7768437 0.78 ACE2 (0.50) ACE2TTRGRM1MEN1CYP1A2
SCHEMBL5874054 0.78 ACE2 (0.51) AKR1C3AKR1C2SRD5A2RXRARXRB
SCHEMBL827082 0.76 RXRA (0.48) SRD5A2RXRARXRBRXRGKIF11
SCHEMBL31319449 0.76 RXRA (0.48) SRD5A2RXRARXRBRXRGKIF11
SCHEMBL27671698 0.75 SRD5A2 (0.43) AKR1C3AKR1C2SRD5A2RXRARXRB
SCHEMBL4577143 0.75 ACE2 (0.56) ACE2TTRGRM1MEN1CYP1A2
SCHEMBL31401118 0.75 GRM1 (0.50) RXRARXRBACE2GRM1MEN1
SCHEMBL23675536 0.75 PDE2A (0.61) PDE2A
SCHEMBL22717043 0.75 PDE2A (0.61) PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250106-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 US disclosed
US-20230250106-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 US disclosed
US-20230250106-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 US disclosed
WO-2022015977-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2022-01-20 WO disclosed
WO-2022015977-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2022-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250106-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 AKR1C3 4665/4885AKR1C2 4416/4885SRD5A2 4081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.